Literature DB >> 10387041

Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.

J L Martin1, J Begun, A Schindeler, W A Wickramasinghe, D Alewood, P F Alewood, D A Bergman, R I Brinkworth, G Abbenante, D R March, R C Reid, D P Fairlie.   

Abstract

High-resolution crystal structures are described for seven macrocycles complexed with HIV-1 protease (HIVPR). The macrocycles possess two amides and an aromatic group within 15-17 membered rings designed to replace N- or C-terminal tripeptides from peptidic inhibitors of HIVPR. Appended to each macrocycle is a transition state isostere and either an acyclic peptide, nonpeptide, or another macrocycle. These cyclic analogues are potent inhibitors of HIVPR, and the crystal structures show them to be structural mimics of acyclic peptides, binding in the active site of HIVPR via the same interactions. Each macrocycle is restrained to adopt a beta-strand conformation which is preorganized for protease binding. An unusual feature of the binding of C-terminal macrocyclic inhibitors is the interaction between a positively charged secondary amine and a catalytic aspartate of HIVPR. A bicyclic inhibitor binds similarly through its secondary amine that lies between its component N-terminal and C-terminal macrocycles. In contrast, the corresponding tertiary amine of the N-terminal macrocycles does not interact with the catalytic aspartates. The amine-aspartate interaction induces a 1.5 A N-terminal translation of the inhibitors in the active site and is accompanied by weakened interactions with a water molecule that bridges the ligand to the enzyme, as well as static disorder in enzyme flap residues. This flexibility may facilitate peptide cleavage and product dissociation during catalysis. Proteases [Aba67,95]HIVPR and [Lys7,Ile33,Aba67,95]HIVPR used in this work were shown to have very similar crystal structures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10387041     DOI: 10.1021/bi990174x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Keith Romano; Celia A Schiffer
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy.

Authors:  Moses Prabu-Jeyabalan; Ellen A Nalivaika; Nancy M King; Celia A Schiffer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach.

Authors:  E Prabhu Raman; Wenbo Yu; Sirish K Lakkaraju; Alexander D MacKerell
Journal:  J Chem Inf Model       Date:  2013-11-25       Impact factor: 4.956

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.